Header Forschung

Translational Medical Oncology, Prof. Dr. Hanno Glimm

The Department for Translational Medical Oncology investigates the molecular and cellular mechanisms for cancer development, proliferation and evolution. The department engages in clinical as well as experimental activities to ensure a rapid turnaround of scientific results into clinical application and clinical outcome into new hypotheses. Experimentally, high-throughput, multi-parametric molecular profiling is used to discover differences in the genome of tumor and normal cells to identify novel targets for cancer therapy on the genomic or cellular level.

The group develops suitable model systems to functionally and mechanistically characterize their impact and assess the potential for clinical application. Clinically, a dedicated personalized oncology outpatient clinic provides consulting appointments to initiate innovative diagnostic approaches, and organizes a tumor board to discuss results of genetic tumor profiling and molecularly guided treatment strategies.

Understanding and targeting alterations in cancer

Unique alterations within tumor cells can be targets for novel treatment approaches. Scientists of the department for Translational Medical Oncology are working on identifying pivotal gene alterations and cellular subtypes that are responsible for initiating or fueling tumor growth and metastasis formation. Within individual patient tumors, a small fraction of all cells drives long-term tumor growth and metastases. Targeting this tumor-initiating cells (TIC) activity is essential to improve the long-term outcome in advanced solid cancers. The lab has developed and extensively characterized a bank of primary in vitro and in vivo models derived from solid patient tumors, e.g. CRC, PDAC and sarcomas. These functionally and genetically heterogeneous models are utilized to identify therapy relevant alterations and synthetic lethal interactions, e.g. by large scale shRNA knockdown or overexpression screening approaches. Following functional testing of potential therapeutic target alterations, targeted therapeutic strategies are developed and translated into the clinic.

The Glimm Lab, represented by the Department of Translational Medical Oncology in Dresden and the Translational Functional Cancer Genomics group in Heidelberg, welcomes researchers at both NCT partner sites to join their expertise in collaborating on these research questions.

Dr. Claudia Ball
Senior Scientist, Head of Laboratory
Email: claudia.ball(at)nct-dresden.de

NCT MASTER Registry trial for patients

In an interdisciplinary approach, new discoveries are directly transferred into treatment recommendations using the NCT/DKTK MASTER registry trial. The NCT-MASTER (Molecularly Aided Stratification for Tumor Eradication) protocol consents young patients or patients with rare tumor diseases for molecular diagnostics approaches with the explicit purpose of evaluating and stratifying for the best molecular treatment strategy and enrolment in diagnostic and therapeutic trials. The NCT MASTER is a joint NCT program between NCT Heidelberg and NCT Dresden. You can find more information about registering for the program here or download the flyer here.

Center for Personalized Oncology

The NCT Dresden Center for Personalized Oncology aims at translating latest research as well as innovative technologies and cancer therapies into clinical practice. A dedicated personalized oncology outpatient clinic provides consulting appointments to discuss innovative diagnostic approaches, results of genetic tumor profiling and molecularly guided treatment strategies. Clinical data and results of molecular analyses as well as potential therapeutic implications are discussed within a personalized oncology tumorboard participated by an interdisciplinary team of specialists in molecular diagnostics, targeted cancer therapy as well as involved clinical departments.

Dr. Christoph Heining
Senior Attending Physician
Email: christoph.heining(at)nct-dresden.de

Team members

 

 

 

Prof. Dr. Hanno Glimm
Head of Department
Translational Medical Oncology
Phone: +49 (0)351 458 5531
E-Mail: hanno.glimm(at)nct-dresden.de

Ramona Striegler
Secretary
Phone: +49 (0)351 458 5531
E-Mail: ramona.striegler(at)nct-dresden.de

Dr. Daniela Richter
Scientific and Administrative Coordinator
Phone: +49 (0)351 458 5539
E-Mail: daniela.richter(at)nct-dresden.de

Wünsche P, Eckert ESP, Holland-Letz T, Paruzynski A, Hotz-Wagenblatt A, Fronza R, Rath T, Gil Farina I, Schmidt M, von Kalle C, Klein C, Ball CR, Herbst F, Glimm H: Mapping Active Gene regulatory Regions in Human Repopulating Long-term HSCs. Cell Stem Cell, in press.

Heining C, Horak P, Uhrig S, Codo PL, Klink B, Hutter B, Fröhlich M, Bonekamp D, Richter D, Steiger K, Penzel R, Endris V, Ehrenberg KR, Frank S, Kleinheinz K, Toprak UH, Schlesner M, Mandal R, Schulz L, Lambertz H, Fetscher S, Bitzer M, Malek NP, Horger MS, Giese NA, Strobel O, Hackert T, Springfeld C, Feuerbach L, Bergmann F, Schröck E, von Kalle C, Weichert W, Scholl C, Ball CR, Stenzinger A, Brors B, Fröhling S, Glimm H. NRG1 Fusions in KRAS Wild-type Pancreatic Cancer. Cancer Discov. 2018 May 25

Horak P, Klink B, Heining C, Gröschel S, Hutter B, Fröhlich M, Uhrig S, Hübschmann D, Schlesner M, Eils R, Richter D, Pfütze K, Geörg C, Meißburger B, Wolf S, Schulz A, Penzel R, Herpel E, Kirchner M, Lier A, Endris V, Singer S, Schirmacher P, Weichert W, Stenzinger A, Schlenk RF, Schröck E, Brors B, von Kalle C, Glimm H, Fröhling S.: Precision oncology based on omics data: The NCT Heidelberg experience. Int J Cancer. 2017 Sep 1;141(5):877-886.

Giessler KM, Kleinheinz K, Huebschmann D, Balasubramanian GP, Dubash TD, Dieter SM, Siegl C, Herbst F, Weber S, Hoffmann CM, Fronza R, Buchhalter I, Paramasivam N, Eils R, Schmidt M, von Kalle C, Schneider M, Ulrich A, Scholl C, Fröhling S, Weichert W, Brors B, Schlesner M, Ball CR, Glimm H.: Genetic subclone architecture of tumor clone-initiating cells in colorectal cancer. J Exp Med. 2017 Jul 3;214(7):2073-2088.

Dieter SM, Glimm H, Ball CR.: Colorectal cancer-initiating cells caught in the act. EMBO Mol Med. 2017 Jul;9(7):856-858.

Ball CR, Oppel F, Ehrenberg KR, Dubash TD, Dieter SM, Hoffmann CM, Abel U, Herbst F, Koch M, Werner J, Bergmann F, Ishaque N, Schmidt M, von Kalle C, Scholl C, Fröhling S, Brors B, Weichert W, Weitz J, Glimm H.: Succession of transiently active tumor-initiating cell clones in human pancreatic cancer xenografts. EMBO Mol Med. 2017 Jul;9(7):918-932.

Dieter SM, Giessler KM, Kriegsmann M, Dubash TD, Möhrmann L, Schulz ER, Siegl C, Weber S, Strakerjahn H, Oberlack A, Heger U, Gao J, Hartinger EM, Oppel F, Hoffmann CM, Ha N, Brors B, Lasitschka F, Ulrich A, Strobel O, Schmidt M, von Kalle C, Schneider M, Weichert W, Ehrenberg KR, Glimm H, Ball CR.: Patient-derived xenografts of gastrointestinal cancers are susceptible to rapid and delayed B-lymphoproliferation. Int J Cancer. 2017 Mar 15;140(6):1356-1363.

Horak P, Fröhling S, Glimm H.: Integrating next-generation sequencing into clinical oncology: strategies, promises and pitfalls. ESMO Open. 2016 Nov 18;1(5):e000094. eCollection 2016.

Weischenfeldt J, Dubash T, Drainas AP, Mardin BR, Chen Y, Stütz AM, Waszak SM, Bosco G, Halvorsen AR, Raeder B, Efthymiopoulos T, Erkek S, Siegl C, Brenner H, Brustugun OT, Dieter SM, Northcott PA, Petersen I, Pfister SM, Schneider M, Solberg SK, Thunissen E, Weichert W, Zichner T, Thomas R, Peifer M, Helland A, Ball CR, Jechlinger M, Sotillo R, Glimm H, Korbel JO.: Pan-cancer analysis of somatic copy-number alterations implicates IRS4 and IGF2 in enhancer hijacking. Nat Genet. 2017 Jan;49(1):65-74.

Dubash TD, Hoffmann CM, Oppel F, Giessler KM, Weber S, Dieter SM, Hüllein J, Zenz T, Herbst F, Scholl C, Weichert W, Werft W, Benner A, Schmidt M, Schneider M, Glimm H, Ball CR.: Phenotypic differentiation does not affect tumorigenicity of primary human colon cancer initiating cells. Cancer Lett. 2016 Feb 28;371(2):326-33.

Thesis topics

The department constantly offers thesis topics for highly motivated Bsc-, Msc- or MD students. If you are interested, please send your informal application to us via email.

Jobs

We are currently looking for:

Hematologist
Physician in training for hematology/oncology
PhD students (117/2018)
StudyNurse (115/2018)

For details please check the NCT job website.